Lactobacillus Casei Rhamnosus
Biliary Atresia
National Taiwan University HospitalN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Biliary Atresia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MELOXIDOLOR Yonsei University | Phase 4 | BB |
Pentoxifylline Baylor College of Medicine | Phase 2 | CCC |
Vancomycin Sacramento Pediatric Gastroenterology | Phase 1 | CC |
CEFACLOR ANHYDROUS Children's Hospital of Fudan University | N/A | D |
IMIPENEM Children's Hospital of Fudan University | N/A | D |
View all 11 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →